<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>LA031390-0143</title>
	</head>
	<body>
		<main>
			<p><P> March 13, 1990, Tuesday, P.M. Final  </P> <P> P.M. BRIEFING;  </P> <P> RORER, P&amp;G PLAN JOINT VENTURE  </P> <P> Rorer Group Inc. today announced an alliance with Procter &amp; Gamble Co. to  develop and market prescription and over-the-counter pharmaceutical products.  </P> <P> The move comes one day after the suburban Philadelphia-based company announced  a $1.7-billion agreement to merge operations with the pharmaceuticals  operations of Rhone-Poulenc of Paris.  </P> <P> Under the terms of today's joint venture, Procter &amp; Gamble will obtain  exclusive U.S. marketing and distribution rights to Rorer's line of  over-the-counter pharmaceuticals such as Maalox, Ascriptin and Perdiem.  </P> <P> Rorer, which will continue to manufacture the drugs, will gain rights to  develop and market De-Nol, an anti-ulcer drug, and other prescription  gastrointestinal compounds that Procter &amp; Gamble has been developing.  </P> <P> Rorer will retain ownership of its brands, while Procter &amp; Gamble will  receive royalty payments for the prescription products. Both companies will  share in the growth of the business.  </P></p>
		</main>
</body></html>
            